Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from Haleon PLC ( (GB:HLN) ).
Haleon PLC has announced the total number of shares issued as of January 31, 2025, which stands at 9,083,725,919 ordinary shares, with 29,580,205 held as treasury shares. This update indicates that there are 9,054,145,714 ordinary shares with voting rights, which is crucial for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. This information is essential for stakeholders to determine their interest in the company.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, operating in the oral health, pain relief, respiratory health, digestive health, and vitamins, minerals, and supplements sectors. The company is known for its trusted brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, which are based on scientific innovation and deep human understanding, aiming to deliver better everyday health with humanity.
YTD Price Performance: -0.72%
Average Trading Volume: 22,852,884
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £33.92B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.
